Endothelin and phenylephrine alter CapZ dynamics through PIP2- and PKC-dependent pathways, which may destabilize the existing sarcomeric framework and permit remodeling during cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
May inform hypertrophy remodeling mechanisms; hypothesis-generating for PIP2/PKC-targeted therapies pending in vivo human data.
Hartman et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: